Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from VistaGen Therapeutics ( (VTGN) ).
On August 7, 2025, Vistagen reported its fiscal year 2026 first-quarter financial results and provided a corporate update. The company highlighted the progress of its lead program, fasedienol, for treating social anxiety disorder, with key trial results expected in late 2025 and early 2026. Vistagen is optimistic about the potential impact of fasedienol, as there is currently no FDA-approved acute treatment for social anxiety disorder. The company is also advancing other intranasal pherine product candidates for major depressive disorder and women’s health conditions. Financially, Vistagen reported increased R&D expenses due to its ongoing trials and a net loss of $15.1 million for the quarter ended June 30, 2025.
The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.
VistaGen Therapeutics exhibits a mixed profile. The company benefits from strong technical momentum and positive corporate developments, such as strategic hires and funding initiatives. However, these strengths are counterbalanced by ongoing financial difficulties, including negative profitability and cash flow, and valuation concerns. The stock score reflects a cautious stance, recognizing both the potential and the risks involved.
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
Vistagen, headquartered in South San Francisco, CA, is a late clinical-stage biopharmaceutical company specializing in neuroscience. The company focuses on developing and commercializing intranasal product candidates called pherines, which are designed to activate peripheral receptors on human nasal chemosensory neurons to modulate brain areas involved in behavior and autonomic nervous system activity. Vistagen aims to provide safer alternatives to existing pharmacological treatments for conditions like social anxiety disorder, major depressive disorder, and women’s health issues such as menopausal hot flashes.
Average Trading Volume: 281,008
Technical Sentiment Signal: Sell
Current Market Cap: $87.19M
See more insights into VTGN stock on TipRanks’ Stock Analysis page.